secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADMA BIOLOGICS, INC. (ADMA)
CIK:        0001368514
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001140361-24-045657
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ADMA Biologics Q3 total revenue $119.8M (+78% YoY); GAAP net income $35.9M (+1,300%)
--------------------------------------------------------------------------------

- Revenue $119.8M (+78% YoY); GAAP net income $35.9M (+1,300%); Adj. EBITDA $45.4M (+256%)
- FY2024 guidance raised: revenue >$415M (from >$400M), GAAP net income >$120M (from >$105M), Adj. EBITDA >$160M (from >$150M)
- FY2025 guidance raised: revenue >$465M, net income >$165M, Adj. EBITDA >$215M
- Appointed KPMG as new independent registered public accounting firm, replacing CohnReznick after 17 years
- ASCENIV now >50% of revenue; sBLA filing planned for label expansion; pediatric study database lock in Q4 2024

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1368514/000114036124045657/0001140361-24-045657-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1368514/000114036124045657/ef20038149_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-045657

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer